首页> Nature medicine> Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial.

导出 OA

翻译打印收藏纠错

第一作者： Jordi,Rodón

第一单位： The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrodon@mdanderson.org.

作者： Jordi,Rodón ^[1] ; Silvia,Damian ^[2] ; Muhammad,Furqan ^[3] ; Jesús,García-Donas ^[4] ; Hiroo,Imai ^[5] ; Antoine,Italiano ^[6] ; Iben,Spanggaard ^[7] ; Makoto,Ueno ^[8] ; Tomoya,Yokota ^[9] ; Maria Luisa,Veronese ^[10] ; Natalia,Oliveira ^[10] ; Xin,Li ^[11] ; Aidan,Gilmartin ^[11] ; Michael,Schaffer ^[11] ; Lipika,Goyal ^[12]

作者单位： The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jrodon@mdanderson.org. ^[1] Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. ^[2] University of Iowa, Iowa City, IA, USA. ^[3] Centro Integral Oncologico Clara Campal, Madrid, Spain. ^[4] Tohoku University Hospital, Sendai-Shi, Japan. ^[5] Institut Bergonié, Bordeaux, France.;Faculty of Medicine, University of Bordeaux, Bordeaux, France. ^[6] Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark. ^[7] Kanagawa Cancer Center, Yokohama, Japan. ^[8] Shizuoka Cancer Center, Shizuoka, Japan. ^[9] Incyte International Biosciences Sàrl, Morges, Switzerland. ^[10] Incyte Corporation, Wilmington, DE, USA. ^[11] Mass General Cancer Center, Harvard Medical School, Boston, MA, USA. lgoyal@stanford.edu.;Stanford Cancer Center, Stanford School of Medicine, Stanford, CA, USA. lgoyal@stanford.edu. ^[12]